Merck and Daiichi Sankyo Withdraw Lung Cancer Therapy US Approval Bid

Merck and Daiichi Sankyo have withdrawn their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan.

The decision was made after discussions with the US Food and Drug Administration (FDA), which determined that data from a mid-stage clinical study did not meet the requirements needed to support early approval.

The therapy was under review for treating adults with extensive-stage small cell lung cancer whose disease had worsened after standard chemotherapy.